

Sub B1  
12. An isolated human cellular inhibitor of apoptosis protein (c-IAP) comprising at least two of: a first domain comprising SEQ ID NO: 5 or 6, a second domain comprising SEQ ID NO: 7 or 8, and a third domain comprising SEQ ID NO: 9 or 10.

13. An isolated protein according to claim 10 comprising SEQ ID NO:2.

Sub B2  
14. A method of screening for compounds which modulate a human c-IAP interaction with a c-IAP binding target, said method comprising the steps of:

incubating a mixture comprising:

a protein according to claim 10, 11, 12, or 13,

a natural intracellular human c-IAP binding target, wherein said binding target is capable of specifically binding said human c-IAP, and

a candidate agent;

under conditions whereby, but for the presence of said candidate agent, said human c-IAP specifically binds said binding target at a reference affinity; and

detecting the binding affinity of said human c-IAP to said binding target to determine an agent-biased affinity,

wherein a difference between the agent-biased affinity and the reference affinity indicates that said candidate agent modulates a human c-IAP interaction with a natural c-IAP binding target.

15. A method according to claim 14, wherein said c-IAP binding target comprises a TRAF or fragment thereof sufficient to provide for c-IAP-specific binding.

Sub B3  
16. A method of inhibiting TNF-mediated apoptosis in a cell comprising the step of introducing into said cell a protein according to claim 10, 11, 12 or 13 whereby said protein promotes or inhibits TNF-mediated apoptosis in said cell, wherein said method is performed in vitro.